Subject
Pharmacology (medical),Oncology
Reference83 articles.
1. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
2. Foundation medicine receives FDA approval for FoundationOne®CDx as the companion diagnostic for tabrectaTM (capmatinib), the only FDA-approved MET inhibitor for patients with metastatic non-small cell lung cancer with METex14. Available from: https://www.foundationmedicine.com/press-releases/0f19426e-6c6b-4d75-8801-789b6f603eb2. Accessed November 6, 2021.
3. An overview of the c-MET signaling pathway
4. c-MET as a potential therapeutic target and biomarker in cancer
5. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献